Myslenice

The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assessment of major complications (e.g., mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke), delirium, length of stay, pain, and quality of life.

Researchers are evaluating the safety and effectiveness of three different doses of a drug called NMD670 compared to a placebo in adults with Myasthenia Gravis (MG) who have antibodies against AChR or MuSK. This Phase 2 study focuses on patients with MG classified as MGFA class II, III, or IV. The goal is to understand how these doses affect muscle strength and disease symptoms over a short period. Participants will receive tablets of either NMD670 or a placebo twice daily for 21 days. The study includes three dose levels of NMD670, allowing comparison across different amounts of the drug to find the most effective and safe dose. Both NMD670 and placebo are administered in the same way, ensuring a fair comparison. During the 21-day treatment period, researchers will monitor participants closely, assessing changes in muscle strength using the Quantitative Myasthenia Gravis (QMG) total score from the start to day 21. Participants will also be evaluated for safety and tolerability throughout the study. The involvement includes regular assessments to track how the drug affects symptoms and any side effects experienced during the treatment.